Mar 6, 2026 04:40AM
Mar 4, 2026 04:11PM
Feb 3, 2026 06:49AM
Feb 2, 2026 07:00AM
Feb 2, 2026 06:59AM
Jan 13, 2026 10:59AM
Jan 9, 2026 07:02AM Aquestive receives FDA letter citing deficiencies in Anaphylm drug application
Nov 5, 2025 04:27PM
Oct 9, 2025 04:11AM
Oct 8, 2025 07:00AM
Sep 4, 2025 07:00AM
Aug 26, 2025 08:07AM
Aug 19, 2025 07:01AM
Aug 14, 2025 06:01AM Aquestive secures $75 million funding from RTW for Anaphylm launch
Aug 11, 2025 04:26PM
Jul 22, 2025 08:53AM
Jul 15, 2025 07:00AM
Jun 17, 2025 06:39AM
Jun 17, 2025 05:15AM
Jun 16, 2025 07:02AM
Jun 2, 2025 08:50AM Oppenheimer Assumes Aquestive Therapeutics (AQST) at Outperform (correction)
May 13, 2025 03:26PM
May 13, 2025 07:37AM
Apr 1, 2025 07:00AM
Mar 10, 2025 06:49AM
Mar 5, 2025 04:34PM
Mar 3, 2025 01:09PM
Feb 19, 2025 01:08PM Leerink Partners Reiterates Outperform Rating on Aquestive Therapeutics (AQST), PT $13
Feb 18, 2025 04:23AM
Dec 20, 2024 06:52AM
Dec 19, 2024 08:02AM
Dec 17, 2024 06:31AM
Dec 2, 2024 08:40AM
Dec 2, 2024 08:02AM
Nov 6, 2024 09:24AM Aquestive Therapeutics (AQST) PT Raised to $10 at Lake Street Capital Markets
Nov 4, 2024 04:43PM
Oct 25, 2024 05:41AM
Oct 24, 2024 08:03AM
Oct 8, 2024 08:10AM
Sep 30, 2024 06:56AM
Sep 27, 2024 08:32AM
Aug 14, 2024 08:01AM Aquestive Therapeutics (AQST) Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm
Aug 6, 2024 04:46PM
Jul 25, 2024 08:02AM
Jun 25, 2024 08:50AM
Jun 25, 2024 08:00AM

353,174 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All